Table 4.
Cohort 2: demographics of patients who received HGG adjuvant therapy
| Variables | Total (%) N = 2264 |
Chemo and radiation (%) N = 1163 |
Chemo (%) N = 93 |
Radiation (%) N = 270 |
No adjuvant treatment (%) N = 738 |
P-value |
|---|---|---|---|---|---|---|
| Sex, male | 1300 (57.4) | 699 (60.1) | 58 (62.4) | 144 (53.3) | 399 (54.1) | .099 |
| Age (SD) | 54.1 (20.4) | 52.4 (17.3) | 47.3 (23.5) | 57.8 (20.8) | 56.6 (23.6) | <.001 |
| Race | .686a | |||||
| American Indian/Alaska Native | <11 | <11 | <11 | 0 | <11 | |
| Asian | 21 (0.9) | 13 (1.1) | 0 | <11 | <11 | |
| Pacific Islander | 15 (0.7) | <11 | 0 | <11 | <11 | |
| Black | 10 (0.4) | <11 | 0 | <11 | <11 | |
| White | 2208 (97.5) | 1133 (97.4) | 92 (98.9) | 263 (97.4) | 720 (97.6) | |
| More than one race | <11 | 0 | 0 | 0 | <11 | |
| Not listed | <11 | 0 | 0 | 0 | <11 | |
| Ethnicity | .349 | |||||
| Non-Hispanic | 2106 (93.0) | 1071 (92.1) | 88 (94.6) | 253 (93.7) | 694 (94.0) | |
| Marital status | <.001 a | |||||
| Single, never married | 390 (17.2) | 169 (14.5) | 26 (28.0) | 40 (14.8) | 155 (21.0) | |
| Married | 1496 (66.1) | 851 (73.2) | 56 (60.2) | 182 (67.4) | 407 (55.1) | |
| Single, previously married | 346 (15.3) | 133 (11.4) | 10 (10.8) | 44 (16.3) | 159 (21.5) | |
| Not listed | 32 (1.4) | 10 (0.9) | <11 | <11 | 17 (2.3) | |
| Insurance status | <.001 a | |||||
| Uninsured | 94 (4.2) | 48 (4.1) | <11 | 16 (5.9) | 27 (3.7) | |
| Insurance, NOS | 72 (3.2) | 39 (3.4) | <11 | 10 (3.7) | 18 (2.4) | |
| Private insurance | 1003 (44.3) | 623 (53.6) | 44 (47.3) | 102 (37.8) | 234 (31.7) | |
| Medicare and Medicaid | 898 (39.7) | 396 (34.0) | 22 (23.7) | 125 (46.3) | 355 (48.1) | |
| Other government program | 61 (2.7) | 30 (2.6) | <11 | <11 | 22 (3.0) | |
| Not listed | 136 (6.0) | 27 (2.3) | 17 (18.3) | 10 (3.7) | 82 (11.1) | |
| Diagnosis | <.001 a | |||||
| Malignant glioma, NOS | 256 (11.3) | 32 (2.8) | 11 (11.8) | 35 (13.0) | 178 (24.1) | |
| Astrocytoma, anaplastic | 217 (9.6) | 156 (13.4) | <11 | 26 (9.6) | 30 (4.10) | |
| Astrocytoma, diffuse | 66 (2.9) | 18 (1.5) | <11 | 15 (5.6) | 30 (4.1) | |
| Glioblastoma | 1639 (72.4) | 918 (78.9) | 62 (66.7) | 177 (65.6) | 482 (65.3) | |
| Oligodendroglioma, anaplastic | 86 (3.8) | 39 (3.4) | 12 (12.9) | 17 (6.3) | 18 (2.4) | |
| Distance traveled, mi | .801 | |||||
| First facility (SD) | 37.6 (58.3) | 37.4 (57.1) | 31.1 (46.4) | 39.8 (67.8) | N/A | |
| Income quartiles (%) | .007 | |||||
| Q1 (lowest income) | 413 (18.2) | 188 (16.2) | 16 (17.2) | 46 (17.0) | 163 (22.1) | |
| Q2 | 573 (25.3) | 274 (23.6) | 23 (24.7) | 74 (27.4) | 202 (27.4) | |
| Q3 | 641 (28.3) | 338 (29.0) | 27 (29.0) | 83 (30.7) | 193 (26.2) | |
| Q4 (highest income) | 637 (28.1) | 363 (31.2) | 27 (29.0) | 67 (24.8) | 180 (24.4) | |
| Yost Index quartile (%) | .005 | |||||
| Q1 (lowest SES) | 399 (17.6) | 181 (15.6) | 20 (21.5) | 44 (16.3) | 154 (20.9) | |
| Q2 | 570 (25.2) | 270 (23.2) | 21 (22.6) | 72 (26.7) | 207 (28.0) | |
| Q3 | 638 (28.2) | 340 (29.2) | 27 (29.0) | 84 (31.1) | 187 (25.3) | |
| Q4 (highest SES) | 657 (29.0) | 372 (32.0) | 25 (26.9) | 70 (25.9) | 190 (25.7) | |
| RUCA code (%) | .836 | |||||
| Metropolitan | 1938 (85.6) | 988 (85.0) | 85 (91.4) | 237 (87.8) | 628 (85.1) | |
| Micropolitan | 164 (7.2) | 91 (7.8) | <11 | 15 (5.6) | 54 (7.3) | |
| Small town | 96 (4.2) | 52 (4.5) | <11 | 11 (4.1) | 30 (4.1) | |
| Rural | 66 (2.9) | 32 (2.8) | <11 | <11 | 26 (3.5) |
Abbreviations: HGG, high-grade glioma; SD, standard deviation; NOS, not otherwise specified; SES, socioeconomic status; RUCA, Rural-Urban Commuting Area code; N/A, not applicable.
Bold values are significant.
Percentages given out of total number of patients within adjuvant treatment group. Income quartiles, Yost Index Quartiles, and RUCA codes are given as percentages of total within each quartile. Categorical variables compared with Chi-square test. Continuous variables compared with ANOVA test. Categories with less than 11 patients are not explicitly listed to protect patients from possible identification. Distance is not provided for patients not receiving adjuvant therapy because they did not travel to a treatment facility for adjuvant therapy.
aCategorical variables compared with Fisher-Freeman-Halton exact test.